CA2893120C - Modified coiled coil type proteins having improved properties - Google Patents
Modified coiled coil type proteins having improved properties Download PDFInfo
- Publication number
- CA2893120C CA2893120C CA2893120A CA2893120A CA2893120C CA 2893120 C CA2893120 C CA 2893120C CA 2893120 A CA2893120 A CA 2893120A CA 2893120 A CA2893120 A CA 2893120A CA 2893120 C CA2893120 C CA 2893120C
- Authority
- CA
- Canada
- Prior art keywords
- protein
- seq
- imx313
- antigen
- imx313t
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 242
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 228
- 230000001976 improved effect Effects 0.000 title description 25
- 239000000427 antigen Substances 0.000 claims abstract description 132
- 102000036639 antigens Human genes 0.000 claims abstract description 128
- 108091007433 antigens Proteins 0.000 claims abstract description 128
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 99
- 102000035118 modified proteins Human genes 0.000 claims abstract description 53
- 108091005573 modified proteins Proteins 0.000 claims abstract description 53
- 230000005847 immunogenicity Effects 0.000 claims abstract description 44
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 41
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 40
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960002897 heparin Drugs 0.000 claims abstract description 32
- 229920000669 heparin Polymers 0.000 claims abstract description 32
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 27
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 27
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 27
- 230000001965 increasing effect Effects 0.000 claims abstract description 18
- 229920000642 polymer Polymers 0.000 claims abstract description 5
- 108010061100 Nucleoproteins Proteins 0.000 claims description 112
- 102000011931 Nucleoproteins Human genes 0.000 claims description 110
- 102000037865 fusion proteins Human genes 0.000 claims description 58
- 108020001507 fusion proteins Proteins 0.000 claims description 58
- 239000003446 ligand Substances 0.000 claims description 48
- 102000002689 Toll-like receptor Human genes 0.000 claims description 36
- 108020000411 Toll-like receptor Proteins 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 25
- 230000002163 immunogen Effects 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 230000003834 intracellular effect Effects 0.000 claims description 16
- 206010022000 influenza Diseases 0.000 claims description 15
- 229960005486 vaccine Drugs 0.000 claims description 8
- 101710154606 Hemagglutinin Proteins 0.000 claims description 7
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 7
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 7
- 101710176177 Protein A56 Proteins 0.000 claims description 7
- 241000191967 Staphylococcus aureus Species 0.000 claims description 5
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 5
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 108090000250 sortase A Proteins 0.000 claims description 4
- 241001518086 Bartonella henselae Species 0.000 claims description 3
- 101000971127 Bartonella henselae Autotransporter adhesin BadA Proteins 0.000 claims description 3
- 241001115402 Ebolavirus Species 0.000 claims description 3
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 241000630665 Hada Species 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 3
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 3
- 241000588650 Neisseria meningitidis Species 0.000 claims description 3
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 3
- 241000607447 Yersinia enterocolitica Species 0.000 claims description 3
- 229940092524 bartonella henselae Drugs 0.000 claims description 3
- 229940098232 yersinia enterocolitica Drugs 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 29
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract description 11
- 239000004475 Arginine Substances 0.000 abstract description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract description 4
- 239000004472 Lysine Substances 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 221
- 230000004044 response Effects 0.000 description 71
- 239000013612 plasmid Substances 0.000 description 54
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 46
- 241000699670 Mus sp. Species 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 28
- 239000002671 adjuvant Substances 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 25
- 238000002965 ELISA Methods 0.000 description 24
- 229920002684 Sepharose Polymers 0.000 description 24
- 238000002649 immunization Methods 0.000 description 24
- 108091034117 Oligonucleotide Proteins 0.000 description 23
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 23
- 239000011780 sodium chloride Substances 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 22
- 230000003053 immunization Effects 0.000 description 20
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 18
- 239000000872 buffer Substances 0.000 description 18
- 230000004927 fusion Effects 0.000 description 18
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 230000027455 binding Effects 0.000 description 16
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 16
- 230000005867 T cell response Effects 0.000 description 14
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 14
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 14
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 229960000187 tissue plasminogen activator Drugs 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 10
- 230000005875 antibody response Effects 0.000 description 10
- 235000009697 arginine Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 9
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 9
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 9
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 9
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 239000013615 primer Substances 0.000 description 9
- 238000011725 BALB/c mouse Methods 0.000 description 8
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 8
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000002523 gelfiltration Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- YYGNTYWPHWGJRM-AAJYLUCBSA-N squalene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C YYGNTYWPHWGJRM-AAJYLUCBSA-N 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- -1 DNA and RNA Chemical class 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000036755 cellular response Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000001488 sodium phosphate Substances 0.000 description 7
- 229910000162 sodium phosphate Inorganic materials 0.000 description 7
- 238000000527 sonication Methods 0.000 description 7
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 238000010162 Tukey test Methods 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000000246 agarose gel electrophoresis Methods 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 238000001543 one-way ANOVA Methods 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 230000003393 splenic effect Effects 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 101150069153 Cp15 gene Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108010041986 DNA Vaccines Proteins 0.000 description 4
- 238000011238 DNA vaccination Methods 0.000 description 4
- 229940021995 DNA vaccine Drugs 0.000 description 4
- 241000588722 Escherichia Species 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101150118742 NP gene Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 239000012505 Superdex™ Substances 0.000 description 4
- 239000008049 TAE buffer Substances 0.000 description 4
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000009918 complex formation Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002794 monomerizing effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 108010011110 polyarginine Proteins 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- PAHHYDSPOXDASW-VGWMRTNUSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO PAHHYDSPOXDASW-VGWMRTNUSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 2
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 101000878457 Macrocallista nimbosa FMRFamide Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 241000212749 Zesius chrysomallus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000009962 secretion pathway Effects 0.000 description 2
- 108010015840 seryl-prolyl-lysyl-lysine Proteins 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- BAAVRTJSLCSMNM-CMOCDZPBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanedioic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 BAAVRTJSLCSMNM-CMOCDZPBSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100481581 Mus musculus Tlr13 gene Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108700034501 Staphylococcus aureus auR Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 1
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- WZFNZVJGDCKNME-UHFFFAOYSA-N n'-(4-chloro-2-methylphenyl)-n,n-dimethylmethanimidamide;hydrochloride Chemical compound [Cl-].C[NH+](C)C=NC1=CC=C(Cl)C=C1C WZFNZVJGDCKNME-UHFFFAOYSA-N 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108010032276 tyrosyl-glutamyl-tyrosyl-glutamic acid Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306560.9 | 2012-12-11 | ||
| EP12306560 | 2012-12-11 | ||
| US201361802836P | 2013-03-18 | 2013-03-18 | |
| US61/802,836 | 2013-03-18 | ||
| PCT/EP2013/076289 WO2014090905A1 (en) | 2012-12-11 | 2013-12-11 | Modified coiled coil type proteins having improved properties |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2893120A1 CA2893120A1 (en) | 2014-06-19 |
| CA2893120C true CA2893120C (en) | 2022-03-15 |
Family
ID=47458800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2893120A Active CA2893120C (en) | 2012-12-11 | 2013-12-11 | Modified coiled coil type proteins having improved properties |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9388225B2 (enExample) |
| EP (1) | EP2931896B1 (enExample) |
| JP (1) | JP6518193B2 (enExample) |
| KR (1) | KR102237130B1 (enExample) |
| CN (1) | CN104981541B (enExample) |
| AU (1) | AU2013357367B2 (enExample) |
| BR (1) | BR112015013387B8 (enExample) |
| CA (1) | CA2893120C (enExample) |
| MX (1) | MX363443B (enExample) |
| PL (1) | PL2931896T3 (enExample) |
| RU (1) | RU2677799C2 (enExample) |
| WO (1) | WO2014090905A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2976357B1 (en) * | 2013-03-18 | 2018-10-17 | Osivax SAS | Influenza nucleoprotein vaccines |
| US10111948B2 (en) | 2014-04-25 | 2018-10-30 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| RU2732013C1 (ru) * | 2019-12-11 | 2020-09-10 | Федеральное бюджетное учреждение науки "Государственный научный центр прикладной микробиологии и биотехнологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ПМБ) | Способ сенсибилизации планшета для иммуноферментного анализа нерастворимыми белковыми антигенами |
| KR102613348B1 (ko) * | 2020-01-07 | 2023-12-13 | 에이치케이이노엔 주식회사 | 알부민 및 코일드코일 형성 도메인이 연결된 융합단백질, 및 이를 이용한 이중 표적 결합체 |
| CN115322247B (zh) * | 2021-05-11 | 2025-07-15 | 中国人民解放军军事科学院军事医学研究院 | 一种新型冠状病毒受体结合区电荷突变体抗原及应用 |
| EP4392066A1 (en) | 2021-08-24 | 2024-07-03 | Osivax | Immunogenic compositions and their use |
| KR20240125000A (ko) | 2021-12-22 | 2024-08-19 | 오시벡스 | 백신 조성물 및 이의 용도 |
| CA3253732A1 (en) | 2022-03-22 | 2023-09-28 | Osivax | mRNA VACCINE COMPOSITIONS AND THEIR USE |
| NL2031833B1 (en) | 2022-05-11 | 2023-11-17 | Univ Leiden | Immunotherapeutic compositions and adjuvants |
| CN115779079A (zh) * | 2022-10-01 | 2023-03-14 | 中国人民解放军军事科学院军事医学研究院 | 一种可增强与佐剂协同免疫效力的电荷调控型抗原蛋白 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9222598A (en) * | 1997-09-04 | 1999-03-22 | Stanford University | Reversible immobilization of arginine-tagged moieties on a silicate surface |
| CA2405438C (en) * | 2000-04-07 | 2011-07-12 | University Of Leeds Innovations Limited | Hepatitis b core antigen fusion proteins |
| US7270921B2 (en) * | 2002-02-08 | 2007-09-18 | Kabushiki Kaisha Toshiba | Pattern writing and forming method |
| CA2514841A1 (en) * | 2003-02-02 | 2004-08-19 | Palo Alto Institute Of Molecular Medicine | Cell-killing molecules and methods of use thereof |
| PT1648500E (pt) * | 2003-07-31 | 2014-10-10 | Novartis Vaccines & Diagnostic | Composições imunogénicas para estreptococos piogenes |
| WO2005077976A2 (en) | 2004-02-13 | 2005-08-25 | Avidis Sa | Coiled-coil domains from c4b-binding protein |
| US7960312B2 (en) * | 2005-11-10 | 2011-06-14 | National University Of Corporation Hiroshima University | Method and agent for immobilizing protein via protein bound to silicon oxide-containing substance |
| EP1795540A1 (en) | 2005-11-30 | 2007-06-13 | Imaxio | Multimeric complexes of antigens and an adjuvant |
| DK1996238T3 (da) | 2006-02-28 | 2016-08-01 | Vaxart Inc | Kimæriske adenovirale vektorer og DsRNA som TLR3-agonist |
| GB0706912D0 (en) | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel viral vaccines |
| EP2060586A1 (en) * | 2007-11-14 | 2009-05-20 | PharmaSurgics in Sweden AB | New synthetic arginine substituted peptides and their use |
| GB0918154D0 (en) | 2009-10-16 | 2009-12-02 | Isis Innovation | Mycobacterial vaccines |
| EP2976357B1 (en) * | 2013-03-18 | 2018-10-17 | Osivax SAS | Influenza nucleoprotein vaccines |
-
2013
- 2013-12-11 RU RU2015126105A patent/RU2677799C2/ru active
- 2013-12-11 JP JP2015547006A patent/JP6518193B2/ja active Active
- 2013-12-11 CA CA2893120A patent/CA2893120C/en active Active
- 2013-12-11 BR BR112015013387A patent/BR112015013387B8/pt active IP Right Grant
- 2013-12-11 CN CN201380072637.5A patent/CN104981541B/zh active Active
- 2013-12-11 KR KR1020157018233A patent/KR102237130B1/ko active Active
- 2013-12-11 PL PL13802415T patent/PL2931896T3/pl unknown
- 2013-12-11 AU AU2013357367A patent/AU2013357367B2/en active Active
- 2013-12-11 MX MX2015007421A patent/MX363443B/es unknown
- 2013-12-11 EP EP13802415.3A patent/EP2931896B1/en active Active
- 2013-12-11 WO PCT/EP2013/076289 patent/WO2014090905A1/en not_active Ceased
-
2014
- 2014-12-15 US US14/570,133 patent/US9388225B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2893120A1 (en) | 2014-06-19 |
| BR112015013387B8 (pt) | 2023-01-10 |
| MX363443B (es) | 2019-03-21 |
| EP2931896A1 (en) | 2015-10-21 |
| WO2014090905A8 (en) | 2014-08-21 |
| US9388225B2 (en) | 2016-07-12 |
| BR112015013387B1 (pt) | 2022-12-20 |
| CN104981541B (zh) | 2022-06-28 |
| PL2931896T3 (pl) | 2019-07-31 |
| AU2013357367A1 (en) | 2015-06-11 |
| US20150093406A1 (en) | 2015-04-02 |
| KR20150094697A (ko) | 2015-08-19 |
| RU2677799C2 (ru) | 2019-01-21 |
| JP6518193B2 (ja) | 2019-05-22 |
| EP2931896B1 (en) | 2019-01-16 |
| WO2014090905A1 (en) | 2014-06-19 |
| CN104981541A (zh) | 2015-10-14 |
| JP2016501266A (ja) | 2016-01-18 |
| KR102237130B1 (ko) | 2021-04-08 |
| AU2013357367B2 (en) | 2019-10-24 |
| BR112015013387A2 (pt) | 2017-11-14 |
| MX2015007421A (es) | 2015-12-07 |
| RU2015126105A (ru) | 2017-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2893120C (en) | Modified coiled coil type proteins having improved properties | |
| CN114127101A (zh) | 用于治疗或预防呼吸道感染的亚单位疫苗 | |
| Robinson | Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology | |
| KR20180131584A (ko) | 안정화된 용해성 융합-전 rsv f 단백질 | |
| KR20110088526A (ko) | 구제역 백신 조성물 및 이의 제조 방법 | |
| US9963490B2 (en) | Influenza nucleoprotein vaccines | |
| TWI621627B (zh) | 用於豬生殖與呼吸綜合症及豬環狀病毒關聯疾病之疫苗組成物 | |
| KR102608642B1 (ko) | 폐렴구균 표면 단백질 a의 선택된 알파 나선 도메인 및 프롤린 풍부 도메인을 조합한 폐렴구균 백신 | |
| DK2931896T3 (en) | MODIFIED COILED COIL TYPE WITH IMPROVED PROPERTIES | |
| EP2521563A2 (en) | Methods and compositions for providing protective immunity in the elderly | |
| CN115197303B (zh) | 一种s蛋白的受体结合结构域的突变体及其应用 | |
| EP4509136A1 (en) | Fusion protein and use thereof | |
| CN119836300A (zh) | 狂犬病毒g蛋白及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20181025 |